Adaptimmune Therapeutics plc (ADAP)

Adaptimmune Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	247	180	239	586	834	126
Market Cap Growth	116.44%	-24.70%	-59.17%	-29.79%	561.07%	-79.01%
Enterprise Value	124	55	56	240	485	58
PE Ratio	-	-1.58	-1.45	-3.71	-6.41	-0.92
PS Ratio	13.44	2.99	8.81	95.28	210.82	112.50
PB Ratio	10.12	4.56	2.92	2.85	2.44	1.02
P/FCF Ratio	-2.83	-1.24	-1.40	271.87	-14.92	-1.11
P/OCF Ratio	-2.88	-1.28	-1.69	54.61	-15.57	-1.12
EV/Sales Ratio	6.75	0.92	2.07	39.04	122.62	51.38
EV/EBITDA Ratio	-1.77	-0.54	-0.36	-1.59	-3.97	-0.45
EV/EBIT Ratio	-1.65	-0.49	-0.34	-1.53	-3.74	-0.42
EV/FCF Ratio	-1.94	-0.38	-0.33	111.39	-8.68	-0.51
Debt / Equity Ratio	0.97	0.64	0.28	0.12	0.07	0.21
Debt / EBITDA Ratio	-0.16	-0.25	-0.15	-0.17	-0.19	-0.20
Debt / FCF Ratio	-0.17	-0.17	-0.13	11.82	-0.42	-0.22
Quick Ratio	2.33	2.07	3.31	5.95	9.55	2.74
Current Ratio	2.81	2.85	3.96	6.64	10.19	3.51
Asset Turnover	0.06	0.20	0.07	0.02	0.01	0.01
Return on Equity (ROE)	-234.60%	-134.70%	-132.30%	-61.20%	-39.70%	-80.90%
Return on Assets (ROA)	-55.40%	-37.60%	-45.00%	-38.90%	-30.10%	-61.00%
Return on Capital (ROIC)	-396.65%	-215.82%	-156.22%	-70.11%	-36.56%	-93.74%
Earnings Yield	-66.23%	-63.21%	-69.16%	-26.98%	-15.59%	-108.67%
FCF Yield	-55.92%	-80.80%	-71.59%	0.37%	-6.70%	-90.39%
Buyback Yield / Dilution	-45.08%	-24.73%	-3.47%	-9.36%	-35.72%	-7.78%
Total Shareholder Return	-45.08%	-24.73%	-3.47%	-9.36%	-35.72%	-7.78%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).